<DOC>
	<DOCNO>NCT02549170</DOCNO>
	<brief_summary>This Phase III , prospective , multicenter study two study part ( epoch ) evaluate efficacy , safety , tolerability HYQVIA/HyQvia ( IGI , 10 % recombinant human hyaluronidase ( rHuPH20 ) administer subcutaneously ) maintenance therapy prevent relapse ( Epoch 1 ) GAMMAGARD LIQUID/KIOVIG ( immunoglobulin G intravenous ( IGIV ) 10 % administer intravenously ) treatment CIDP ( Epoch 2 ) . This study enroll adult subject confirm diagnosis CIDP remain stable dose regimen ( monthly equivalent dose 0.4 2.4 g/kg body weight ( BW ) dose interval 2 6 week ) IGIV therapy least 3 month prior screen . In double-blind , placebo-controlled phase study ( Epoch 1 ) , eligible subject randomize 1:1 ratio receive either HYQVIA/HyQvia 0.25 % albumin placebo solution rHuPH20 every two , three , four week double-blind fashion period 6 month relapse . Subjects relapse Epoch 1 enter Epoch 2 receive IGIV treatment period 6 month .</brief_summary>
	<brief_title>Phase III Efficacy , Safety , Tolerability Study HYQVIA/HyQvia GAMMAGARD LIQUID/KIOVIG CIDP</brief_title>
	<detailed_description />
	<mesh_term>Polyradiculoneuropathy</mesh_term>
	<mesh_term>Polyradiculoneuropathy , Chronic Inflammatory Demyelinating</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>1 . Documented diagnosis definite probable Chronic inflammatory demyelinate polyradiculoneuropathy ( CIDP ) ( focal atypical CIDP pure sensory atypical CIDP exclude ) consistent European Federation Neurological Societies/Peripheral Nerve Society ( EFNS/PNS ) 2010 criterion . 2 . Participant respond IgG treatment past , ( partial complete resolution neurological symptom deficit ) , must currently stable dos intravenous immunoglobulin G ( IGIV ) treatment monthly equivalent dose 0.4 2.4 g/kg body weight ( BW ) dose interval 2 6 week least 3 month prior screen . 3 . Inflammatory Neuropathy Cause Treatment disability scale ( INCAT ) disability score 0 7 ( inclusive ) . Participants INCAT score 0 , 1 , 2 ( least 1 point upper extremity ) must history significant disability ie , INCAT disability score 2 ( must exclusively lower extremity ) great past 24 month . 4 . If female childbearing potential , participant must negative pregnancy test screen agree employ highly effective contraceptive measure throughout course study least 30 day last administration investigational product . 5 . Participant willing able sign Informed Consent Form ( ICF ) . 6 . Participant willing able comply requirement protocol . 1 . Focal atypical CIDP pure sensory atypical CIDP . 2 . Any neuropathy cause , include : 1 . Hereditary demyelinate neuropathy 2 . Neuropathies secondary infection , disorder , systemic disease Borrelia burgdorferi infection ( Lyme disease ) , diphtheria ; systemic lupus erythematosus ; polyneuropathy , organomegaly , endocrinopathy edema , Mprotein , skin change ( POEMS ) syndrome ; osteosclerotic myeloma ; diabetic nondiabetic lumbosacral radiculoplexus neuropathy ; lymphoma , amyloidosis 3 . Multifocal motor neuropathy ( MMN ) 4 . Drug , biologic , chemotherapy , toxininduced peripheral neuropathy 3 . Immunoglobulin M ( IgM ) paraproteinemia , include IgM monoclonal gammopathy high titer antibody myelinassociated glycoprotein 4 . Prominent sphincter disturbance . 5 . Central demyelinate disorder ( eg , multiple sclerosis ) . 6 . Any chronic debilitating disease , central nervous disorder cause neurological symptom may interfere assessment CIDP outcome measure ( eg , arthritis , stroke , Parkinson 's disease , diabetic peripheral neuropathy ) ( Participants clinically diagnose diabetes mellitus diabetic peripheral neuropathy , adequate glycemic control Hemoglobin A1C ; also know glycosylated glycated hemoglobin ( HbA1C ) &lt; 7.5 % screening , agree maintain adequate glycemic control study allow . ) 7 . Congestive heart failure ( New York Heart Association ( NYHA ) Class III/IV ) , unstable angina , unstable cardiac arrhythmia , uncontrolled hypertension ( ie , diastolic blood pressure &gt; 100 mmHg and/or systolic blood pressure &gt; 160 mmHg ) . 8 . History deep vein thrombosis thromboembolic event ( eg , cerebrovascular accident , pulmonary embolism ) past 12 month . 9 . Condition ( ) could alter protein catabolism and/or IgG utilization ( eg , proteinlosing enteropathy , nephrotic syndrome ) . 10 . Known history chronic kidney disease , glomerular filtration rate ( GFR ) &lt; 60 mL/min/1.73m^2 estimate base CKDEPI equation ( 2009 ) . 11 . Participant active malignancy require chemotherapy and/or radiotherapy , history malignancy le 2 year complete remission prior screen . Exceptions : adequately treat basal cell squamous cell carcinoma skin , carcinoma situ cervix , stable prostate cancer require treatment . 12 . Clinically significant anemia hemoglobin ( Hgb ) level &lt; 10.0 g/dL screening . 13 . Hypersensitivity adverse reaction ( eg , urticaria , breathe difficulty , severe hypotension , anaphylaxis ) human blood product human IgG , albumin , blood component . 14 . Known allergy hyaluronidase human ( include recombinant human hyaluronidase ) animal origin ( bee wasp venom ) . 15 . Known history immunoglobulin A ( IgA ) deficiency ( &lt; 8 mg/dL ) screening . 16 . Abnormal laboratory value screen : 1 . Serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 2.5x upper limit normal ( ULN ) 2 . Platelet count &lt; 100,000 cells/µL 3 . Absolute neutrophil count ( ANC ) &lt; 1000 cells/µL 17 . Ongoing/active infection hepatitis A virus ( HAV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) Type 1/2 infection . 18 . Use immunomodulatory/immunosuppressive agent past 6 month ( stable , lowdose systemic corticosteroid ( ≤10 mg prednisolone/day equivalent ) nonsystemic corticosteroid allow ) . 19 . Participant receive currently receive treatment corticosteroid within 3 month prior screen . The following exception prednisolone equivalent allow : stable dosage lowdose systemic corticosteroid ( ≤10 mg prednisolone/day equivalent ) nonsystemic corticosteroid ( eg , topical , ophthalmic , inhaled glucocorticoid ) . In addition purpose treat AE nonCIDP intercurrent disease , single corticosteroid dose &gt; 10 mg prednisolone single short term course ≤ 7 day ( Methylprednisolone Dose Pack ) within 3 month prior screen allow . 20 . Participant undergone plasma exchange within 3 month prior screen . 21 . The participant disorder condition investigator 's judgment may impede participant 's participation study , pose increase risk participant , confound result study . 22 . The participant nursing intend begin nurse course study . 23 . Participation another clinical study involve investigational product and/or device within 30 day prior enrollment , plan participation another clinical study course study . 24 . The participant family member employee investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Polyneuropathies</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Peripheral Nervous System Diseases</keyword>
	<keyword>Polyradiculoneuropathy</keyword>
	<keyword>Autoimmune Diseases Nervous System</keyword>
	<keyword>Immunoglobulins</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Demyelinating Diseases</keyword>
	<keyword>Polyradiculoneuropathy , Chronic Inflammatory Demyelinating</keyword>
	<keyword>Neuromuscular Diseases</keyword>
</DOC>